Efficacy and safety of Liraglutide versus high-dose metformin as an initial treatment of type 2 diabetes; open label, randomized controlled trial - Keio study for INitial treatment of type 2 Diabetes with Liraglutide versus Metformin: KIND-LM study

Keio University , School of Mecidicine, Department of Internal Medicine0 个研究点目标入组 110 人开始时间: 2010年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Type 1 diabetes mellitus 2.No informed consent 3.Patients with allergic reaction 4.Pregnant, intention of becoming pregnant 5.Patients with history of lactic acidosis 6.Impaired hepatic function (AST>80IU/L or ALT>80IU/L), Impaired renal function [serum-creatinine; >=1.3mg/dL(male), >=1.2mg/dL(female)] 7.Patients with pre-proliferative retinopathy, or proliferative retinopathy 8.Patients with the gastrointestinal disorder, such as inflam-matory bowel disease and diabetic gastroparesis 9.Patients with history of pancreatitis 10.Patients with a personal history of medullary thyroid carcinoma (MTC) or those from families with known familial MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 11.Non compliance 12.Patients taking systemic corticosteroids 13.Previous liraglutide treatment 14.Any other condition which the attending physician feels would interfere with the study participation.

发起方

Keio University , School of Mecidicine, Department of Internal Medicine